Your browser doesn't support javascript.
loading
Review on anti-alzheimer drug development: approaches, challenges and perspectives.
Abdallah, Abdallah E.
Affiliation
  • Abdallah AE; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University 11884 Cairo Egypt abdulla_emara@azhar.edu.eg.
RSC Adv ; 14(16): 11057-11088, 2024 Apr 03.
Article in En | MEDLINE | ID: mdl-38586442
ABSTRACT
Alzheimer is an irreversible progressive neurodegenerative disease that causes failure of cerebral neurons and disability of the affected person to practice normal daily life activities. There is no concrete evidence to identify the exact reason behind the disease, so several relevant hypotheses emerged, highlighting many possible therapeutic targets, such as acetylcholinesterase, cholinergic receptors, N-methyl d-aspartate receptors, phosphodiesterase, amyloid ß protein, protein phosphatase 2A, glycogen synthase kinase-3 beta, ß-secretase, γ-secretase, α-secretase, serotonergic receptors, glutaminyl cyclase, tumor necrosis factor-α, γ-aminobutyric acid receptors, and mitochondria. All of these targets have been involved in the design of new potential drugs. An extensive number of these drugs have been studied in clinical trials. However, only galantamine, donepezil, and rivastigmine (ChEIs), memantine (NMDA antagonist), and aducanumab and lecanemab (selective anti-Aß monoclonal antibodies) have been approved for AD treatment. Many drugs failed in the clinical trials to such an extent that questions have been posed about the significance of some of the aforementioned targets. On the contrary, the data of other drugs were promising and shed light on the significance of their targets for the development of new potent anti-alzheimer drugs.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: RSC Adv Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: RSC Adv Year: 2024 Document type: Article